Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



BD Diagnostics Presents Integrated Cervical Cancer Testing Solutions at EUROGIN 2013 - BD Totalys™ MultiProcessor Gains CE/IVD Approval in Europe | BD Onclarity™ HPV Assay on the BD Viper™ LT System Featured - BD.com
BD Diagnostics Presents Integrated Cervical Cancer Testing Solutions at EUROGIN 2013

 

PRZOOM - /newswire/ - Florence, Italy, 2013/11/06 - BD Totalys™ MultiProcessor Gains CE/IVD Approval in Europe | BD Onclarity™ HPV Assay on the BD Viper™ LT System Featured - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today at EUROGIN 2013 that the Company has achieved CE/IVD marking of its BD TotalysTM MultiProcessor, an automated instrument that integrates the pre-processing for the BD SurePath™ Liquid-based Pap Test with a molecular aliquot, maintaining sample integrity while improving efficiency in the lab. The Company also supported a symposium at the conference which highlighted the performance of the new BD OnclarityTM HPV Assay on the BD ViperTM LT System, which is pending EU certification.

“These new products are part of BD’s integrated Women's Health portfolio and support full sample chain of custody, high diagnostic accuracy and a clear patient management approach all important elements to improving patient care,” said Paul Holt, Global Market Segment Leader, Women’s Health & Cancer BD Diagnostics. “When laboratories and physicians partner with BD Diagnostics, they benefit from highly customized, leading-edge solutions for the rapidly changing landscape of cervical cancer screening.”

The BD Totalys MultiProcessor provides the ideal balance of automation and flexibility streamlining processes and removing inefficiencies. The highly automated sample preparation for cytology and molecular testing helps enhance lab productivity, while random sample loading reduces hands-on time. The system provides remote diagnostic and service capabilities to maintain optimal system uptime.

The BD Onclarity HPV Assay targets E6/E7 DNA oncogenes and is designed to provide physicians access to broader HPV genotype information to guide informed treatment decisions for their patients. The BD Onclarity HPV Assay reports results on six discrete HR HPV genotypes (16, 18, 45, 31, 51 and 52) with the remaining eight high-risk types reported in three small groups: (33, 58), (35, 39, 68) and (56, 59, 66). High-risk genotype and genotype group results are obtained from the same sample with no additional processing steps.

The BD Onclarity HPV Assay is designed for the BD Viper LT System, a bench-top instrument that automates sample setup, DNA extraction, RT PCR• amplification and detection with minimal lab technician intervention during processing. The BD Viper LT System’s integrated design and ease-of-use supports the adoption in both cytology and molecular laboratory environments.

The BD Onclarity HPV Assay is pending certification in the EU and is expected to launch in Europe and Asia in December 2013.The product is not currently for sale or distribution in the U.S.

Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV).1 Although there are more than 100 HPV genotypes, 14 high risk (HR) genotypes are considered to be cancer-causing.2 Many women with a positive HR HPV result will clear the infection on their own before it progresses towards cervical cancer.3

About BD
BD (bd.com) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

* Real-time polymerase chain reaction

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. 1999. The Journal of pathology 189:12-19
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. 2003. The New England journal of medicine 348:518-27
3. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, et al. 2012. Vaccine 30 Suppl 5:F24-33

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BD Diagnostics Presents Integrated Cervical Cancer Testing Solutions at EUROGIN 2013

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
EUROGIN 2013 | BD
Contact: Lindsay Roman - BD.com 
201-847-4312 Lindsay_Roman[.]bd.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today